FDA Tablet Scoring Guidance Holds Brands, Generics To Single Standard
This article was originally published in The Tan Sheet
Executive Summary
Generic and private label industry concerns that scoring conventions could create barriers to market entry did not win out in the agency’s final tablet scoring guidance. FDA advises firms to contact the agency when questions arise about a product’s scoring being patent-protected.
You may also be interested in...
Split Tablet Stability Testing Leaves Advisory Panel Uniformly Puzzled
FDA wants manufacturers to demonstrate split tablets are safe under ideal conditions, but advisory committee members wonder how useful patients will find the data.
Tablet Scoring Guidance Could Drop Patient Testing Recommendation
FDA’s Advisory Committee for Pharmaceutical Science and Clinical Pharmacology unanimously rejects an idea to test tablet scoring in the relevant patient population, saying there is too much potential variability.
FDA’s Top-Four Tablet Scoring Concerns To Get Advisory Committee Review
The Advisory Committee for Pharmaceutical Science and Clinical Pharmacology will vote on some aspects of FDA’s draft scoring guidance, potentially giving generic industry a clue of future agency actions.